Family Group – Talk Bio

FDA Announces New Rare Disease Approval Programme

1 week ago talkbio0Tagged Accelerated, Approved, Biological Factors, conditional approval pathway, drug review, Endpoints, Infrequent, real-world data, streamlined process, Surrogate, United States Food and Drug Administration

FDA; rare disease; conditional approval pathway; accelerated approval; biologics; drug review; surrogate endpoints; real-world data; streamlined process

Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success

4 weeks ago talkbio0Tagged Biological Science Disciplines, Early-stage, Hatteras, Hatteras Opportunity Fund I, Hatteras Venture Fund VII, HistoSonics exit, medtech, Partner in relationship, startups, venture capital

Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I

Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy

2 months ago talkbio0Tagged Arch of foot, Cancer Therapeutic Procedure, CAR-T, Carl June, Dispatch Bio, Flare platform, Funding, Immunotherapy, Parker Institute for Cancer Immunotherapy, Partner in relationship, Series, Solid Neoplasm, venture

Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment

Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure

5 months ago talkbio0Tagged Alloimmune thrombocytopenia, Biotech pipeline shift, Fetal and neonatal alloimmune thrombocytopenia, Fetus, immune disorder therapy, Infant, Newborn, Mother (person), Phase 2 clinical trial, Rallybio RLYB212

Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift

BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody

6 months ago talkbio0Tagged 30%, BioAtla, CAB, Partner in relationship, Staff

Staff, Partner in relationship, CAB, BioAtla, 30%

Sofinnova Partners Launches Three New Biotechs with €165M Acceleration Fund

6 months ago talkbio0Tagged Acceleration, BioClec, Funds, Partner in relationship, pharmaceutical backing, Sofinnova, venture

Sofinnova Partners, biotech acceleration fund, BioClec, Forth Therapeutics, Signadori Bio, venture capital, pharmaceutical backing

Revitalizing Maternal Health: Nonprofit Leverages Low-Dose Aspirin to Combat Preeclampsia Disparities

8 months ago talkbio0Tagged aspirin, Black Populations, GTPase-Activating Proteins, health disparity, Health Equity, Low-Dose, Mother (person), Pre-Eclampsia, SPIRIN

Preeclampsia, Maternal Health Equity, Low-Dose Aspirin, GAP—SPIRIN, Health Disparities, Black Maternal Health

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

8 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners